Skip to main content
NINGXIA ZHONGKE BIOTECHNOLOGY CO., LTD logo

NINGXIA ZHONGKE BIOTECHNOLOGY CO., LTD — Investor Relations & Filings

Ticker · 600165 ISIN · CNE000000W47 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,434 across all filing types
Latest filing 2026-05-22 Legal Proceedings Report
Country CN China
Listing Shanghai Stock Exchange 600165

About NINGXIA ZHONGKE BIOTECHNOLOGY CO., LTD

http://www.ningkeshengwu.com/

Ningxia Zhongke Biotechnology Co., Ltd. specializes in the research, development, and large-scale production of bio-based chemical materials. The company primarily focuses on long-chain dicarboxylic acids (LCDAs) produced through biological fermentation processes. Its core product portfolio includes sebacic acid and dodecanedioic acid, which serve as essential raw materials for high-performance nylon, lubricants, corrosion inhibitors, and specialized plasticizers. By utilizing advanced biotechnology, the company provides sustainable alternatives to traditional chemical synthesis methods. Its products cater to diverse industrial sectors, including automotive, aerospace, and consumer electronics, emphasizing high purity and environmental efficiency in chemical manufacturing.

Recent filings

Filing Released Lang Actions
ST宁科关于涉及追偿权纠纷诉讼的进展公告
Legal Proceedings Report Classification · 95% confidence The document is an official disclosure by the company detailing the progress and outcome of a civil litigation case (recourse rights dispute), including the first-instance judgment, appeal rights, and its financial impact. This is a direct update on legal proceedings, matching the definition of Legal Proceedings Report (LTR).
2026-05-22 Chinese
ST宁科2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 85% confidence The document is an official announcement of the 2025 Annual General Meeting (AGM) resolutions, detailing meeting attendance, each agenda item, the voting results (numbers and percentages of votes for, against, and abstentions), and legal witness statements. This corresponds to a Declaration of Voting Results & Voting Rights Announcement (DVA).
2026-05-14 Chinese
关于宁夏中科生物科技股份有限公司2025年年度股东会法律意见书
Regulatory Filings Classification · 75% confidence The document is a law firm’s legal opinion letter pertaining to the convening, procedures, attendance qualifications, and voting results of the company’s 2025 Annual General Meeting. It is not an AGM presentation (AGM-R), proxy solicitation (PSI), standalone vote results notice (DVA), or any financial report. Nor does it fit into other specific categories. It is a compliance/legal opinion filing, so it best fits into the fallback “Regulatory Filings” category (RNS).
2026-05-14 Chinese
ST宁科2025年年度股东会材料
AGM Information Classification · 95% confidence The document is titled as "2025 年年度股东会材料" which translates to "2025 Annual General Meeting Materials". It contains detailed agenda items for the 2025 Annual General Meeting (AGM), including announcements, voting methods, reports to be reviewed and voted on, and voting results. The document includes the 2025年度董事会工作报告 (2025 Board of Directors Work Report) and financial discussions, but these are presented as part of the AGM materials rather than standalone annual or interim reports. The content is consistent with materials prepared and distributed for an AGM, including voting ballots and legal opinions. There is no indication that this is the full Annual Report (10-K) or an earnings release (ER), nor is it a simple announcement of a report. The length and detail confirm it is the actual AGM materials. Therefore, the document fits the category AGM Information (AGM-R).
2026-05-08 Chinese
国泰海通证券股份有限公司关于宁夏中科生物科技股份有限公司详式权益变动报告书之2025年年度及2026年第一季度持续督导意见
Regulatory Filings Classification · 95% confidence The document is titled as a "持续督导意见" (continuous supervision opinion) issued by Guotai Haitong Securities Co., Ltd. regarding the detailed equity change report of Ningxia Zhongke Biological Technology Co., Ltd. It covers the period from the 2025 annual report and the 2026 first quarter report, indicating it is a supervisory opinion on equity changes and compliance with regulations during a takeover or restructuring process. The document includes detailed descriptions of equity changes, shareholding structure, compliance with laws, and ongoing supervisory opinions by the financial advisor. It is not the original detailed equity change report itself but a continuous supervisory opinion related to the equity change report and takeover process. This type of document is a regulatory filing related to ongoing compliance and supervision rather than a direct financial report or announcement of voting results. Therefore, the best fitting category is Regulatory Filings (RNS). The document length (5765 characters) and content confirm it is a substantive regulatory compliance report rather than a brief announcement or a full annual/interim report.
2026-05-07 Chinese
宁夏中科生物科技股份有限公司2025年度审计报告
Audit Report / Information Classification · 99% confidence The document is titled “2025年度审计报告” for 宁夏中科生物科技股份有限公司 and contains the full auditor’s opinion, basis of opinion, key audit matters, and detailed consolidated and parent-company financial statements and notes. It is a standalone audit report (not a full Annual Report or mere announcement), matching the definition of an Audit Report / Information. FY 2025
2026-04-23 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.